Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade GliomasHoward A. Fine, Craig B. Borkowf, Tracy T. Batchelor et al.|Journal of Clinical Oncology|2003Cited by 174
Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigationSeth A. Wander, Aditya Bardia, Douglas S. Micalizzi et al.|Cancer Research|2022Cited by 1